Chemotherapy Plus Radiation Therapy in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients with refractory or relapsed Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Etoposide phosphate; Ifosfamide; Isophosphamide mustard; Lenograstim; Melphalan

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed residual or relapsed Hodgkin's lymphoma following conventional dose standard chemotherapy

• Presence of the following prognostic factors are allowed:

• B symptoms (fever, weight loss, night sweats)

• Extranodal disease

• Complete remission of less than 1 year duration

PATIENT CHARACTERISTICS:

Age:

• Not specified

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2.0 mg/dL unless history of Gilbert's disease

• No chronic active or persistent hepatitis

Renal:

• No history of chronic renal insufficiency

• Creatinine no greater than 1.5 mg/dL OR

• Creatinine clearance at least 60 mL/min

Cardiovascular:

• No myocardial infarction within the past 6 months

• No unstable angina

• No significant cardiac arrhythmias other than chronic atrial fibrillation

• Ejection fraction at least 50%

Pulmonary:

• DLCO at least 50%

Other:

• No uncontrolled infection

• HIV negative

• At least 5 years since prior malignancy except:

• Curatively treated cutaneous basal cell carcinoma

• Carcinoma in situ of the cervix

• Not pregnant or nursing

• Fertile women must use effective contraception

PRIOR CONCURRENT THERAPY:

• Must have failed conventional dose standard chemotherapy